Insecticid.India Q4 FY23 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 2
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Targeting double-digit revenue growth of 10% to 12% in fiscal year 2024.
- Expecting significant growth in exports, aiming to double export sales compared to the previous year.
- Planning gross sales of over INR 800 crores in Q1, supported by new product launches and higher sales targets.
- New patented and branded products (e.g., Shinwa, Hachiman, Torry, Mission) expected to contribute substantially, with Focused Maharatna and Maharatna segments projected to account for at least 60% of sales in FY '24.
- Inventory liquidation and market normalization anticipated to improve margins and profitability.
- Anticipate recovery and growth as agricultural season picks up, with positive impact expected from monsoon timing and market conditions.
- Expansion of product portfolio and R&D initiatives aimed at sustaining growth and entering new markets continuously.
See what Insecticid.India management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no mention of any current or future fundraising plans through debt or equity in the provided transcript.
- The management did not discuss raising capital or issuing shares during the call.
- Rajesh Aggarwal confirmed no promoter share offloading or reduction has occurred; in fact, promoter holding increased due to past buyback.
- The focus is on internal growth through new product launches, R&D, backward integration, and improving profitability rather than external fundraising.
- No specific financial plans involving raising capital were shared for the near future.
See what Insecticid.India management said on order book — free account, 30 seconds.
Capex plans
Yes- Completed project at Chopanki; plant is up and functioning with full-fledged technical production.
- New molecules from Chopanki unit have already been launched in the market.
- Announced a new plant at Sotanala (Behror); company in final stages of acquisition with registry expected in early June.
- Plans to start production of formulations and biologicals from the new site, with technicals production as Phase 2 in a phased approach.
- Focus on backward integration initiatives supporting business momentum and growth.
Track Insecticid.India — get its next earnings analysis in your feed
Margin guidance
Category 2- FY '24 expected to be challenging due to inventory liquidation and market pressures, but growth is anticipated.
- Revenue growth target for FY '24 is double-digit, around 10%-12%.
- EBITDA margin guidance for FY '24 is subdued at 9%-10%, with improvement expected post Q1 as lower cost inventories come into effect.
- The company aims to increase profitability beyond current 10% EBITDA margin to 12%+ in FY '25 when market normalizes and new, higher-margin patented products gain traction.
- New product launches, including patented products, expected to drive better margins and growth over the next few years.
- Export growth projected to double in FY '24, potentially boosting earnings.
- Performance is expected to improve from Q2 FY '24 onwards, assuming favorable monsoon and easing of Chinese pricing pressures.
- Long-term growth supported by R&D, backward integration, introduction of mega brands, and new markets expansion.
Order book
- The transcript does not explicitly mention a specific current or expected order book or pending orders value.
- Rajesh Aggarwal mentions strong sales targets, notably planning gross sales of INR 800 crores-plus in the first quarter, indicating a strong order pipeline.
- Demand for products remains good domestically, with no significant stocks in the market, suggesting steady off-take.
- Chinese inventory is still flowing into the market, which affects pricing but also indicates ongoing procurement and orders.
- The company is optimistic about growth from Q2 onwards, assuming normalization post monsoon.
- While exact order book figures aren’t disclosed, the focus on inventory liquidation and ambitious Q1 sales targets implies a healthy pending order scenario.
How does Insecticid.India rank vs peers in Fertilizers & Agrochemicals?
Pro featureHow does Insecticid.India rank in Fertilizers & Agrochemicals?
Compare Insecticid.India against every Fertilizers & Agrochemicals company (Q4 FY23) on revenue, margins and earnings-call signals.
Continue your research
What Insecticid.India's management said in earlier quarters
Others in Fertilizers & Agrochemicals this season
- GSP Crop Science (Q1 FY27)
Capacity utilization indicates room for growth: 70-75% for technical and 25-30% for formulations. Key concall takeaways from GSP Crop Science Ltd's Q1 FY27…
- Sharda Cropchem (Q4 FY25)
Globally, the company’s current 4%-5% global market share offers scope to increase, meaning a 1% global share gain equates to 20%-25% volume growth for them…
- Sumitomo Chemi. (Q2 FY26)
Domestic sales grew 11% YoY in H1 FY '25-'26, with improved farmer connect initiatives like 'Every Day Farmers Day' enhancing demand. Key concall takeaways…
- Indogulf Cropsci (Q3 FY26)
The value of these export orders in hand is approximately INR 4 to 5 crores. Key concall takeaways from Indogulf Cropsci's Q3 FY26 earnings call — and how it…